C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 151.05 INR 0.71%
Market Cap: 225B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

EV/FCFF
Enterprise Value to FCFF

123.4
Current
107.4
Median
19.3
Industry
Higher than median
Higher than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
123.4
=
Enterprise Value
221.9B INR
/
FCFF
1.8B INR
All Countries
All Countries
Close
Market Cap EV/FCFF
IN
Concord Biotech Ltd
NSE:CONCORDBIO
225B INR 123.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -15 979 072.3
US
Eli Lilly and Co
NYSE:LLY
755.8B USD -343.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 13 236.9
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 40.7
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 17.6
US
Merck & Co Inc
NYSE:MRK
251.8B USD 18.3
CH
Roche Holding AG
SIX:ROG
200.1B CHF 41.3
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 375.7
CH
Novartis AG
SIX:NOVN
171.5B CHF 15.2
US
Pfizer Inc
NYSE:PFE
151.5B USD 43.7

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Summary
CONCORDBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CONCORDBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CONCORDBIO stock valuation using valuation multiples.
Wall Street Estimates
CONCORDBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CONCORDBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.